Dendritic cell targeting effectively boosts T cell responses elicited by an HIV multiepitope DNA vaccine

Frontiers in Immunology

Volumn 8, Issue FEB, 2017, Pages

  Apostólico, Juliana de Souza ^a,b   Santos Lunardelli, Victória Alves ^a   Yamamoto, Marcio Massao ^c   Santos Souza, Higo Fernando ^c   Cunha Neto, Edecio ^b,c   Boscardin, Silvia Beatriz ^b,c   Rosa, Daniela Santoro ^a,b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Institute of Investigation in Immunology iii   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

CD4+ T cell; Dendritic cells; HIV; Monoclonal antibody; Multiepitope vaccine

Indexed keywords

CELL SURFACE RECEPTOR; DNA VACCINE; EPITOPE; TOLL LIKE RECEPTOR 3;

AGAR GEL ELECTROPHORESIS; ANIMAL EXPERIMENT; ARTICLE; BINDING ASSAY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOASSAY; IMMUNOBLOTTING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; SPLEEN CELL;

EID: 85014363837     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.00101     Document Type: Article

References (69)

1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 361(23):2209-20. doi: 10.1056/NEJMoa0908492
2. McElrath MJ, Haynes BF. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity (2010) 33(4):542-54. doi:10.1016/j.immuni.2010.09.011
3. de Souza MS, Ratto-Kim S, Chuenarom W, Schuetz A, Chantakulkij S, Nuntapinit B, et al. The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol (2012) 188(10):5166-76. doi:10.4049/jimmunol.1102756
4. Hansen SG, Piatak M Jr, Ventura AB, Hughes CM, Gilbride RM, Ford JC, et al. Immune clearance of highly pathogenic SIV infection. Nature (2013) 502(7469):100-4. doi:10.1038/nature12519
5. Janes H, Friedrich DP, Krambrink A, Smith RJ, Kallas EG, Horton H, et al. Vaccine-induced gag-specific T cells are associated with reduced viremia after HIV-1 infection. J Infect Dis (2013) 208(8):1231-9. doi:10.1093/infdis/jit322
6. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science (1997) 278(5342):1447-50. doi:10.1126/science.278.5342.1447
7. Sacha JB, Giraldo-Vela JP, Buechler MB, Martins MA, Maness NJ, Chung C, et al. Gag-and Nef-specific CD4+ T cells recognize and inhibit SIV replication in infected macrophages early after infection. Proc Natl Acad Sci U S A (2009) 106(24):9791-6. doi:10.1073/pnas.0813106106
8. Pancre V, Delhem N, Yazdanpanah Y, Delanoye A, Delacre M, Depil S, et al. Presence of HIV-1 Nef specific CD4 T cell response is associated with non-progression in HIV-1 infection. Vaccine (2007) 25(31):5927-37. doi:10.1016/j.vaccine.2007.05.038
9. Ferre AL, Hunt PW, McConnell DH, Morris MM, Garcia JC, Pollard RB, et al. HIV controllers with HLA-DRB1*13 and HLA-DQB1*06 alleles have strong, polyfunctional mucosal CD4+ T-cell responses. J Virol (2010) 84(21):11020-9. doi:10.1128/JVI.00980-10
10. Ranasinghe S, Soghoian DZ, Lindqvist M, Ghebremichael M, Donaghey F, Carrington M, et al. HIV-1 antibody neutralization breadth is associated with enhanced HIV-specific CD4+ T cell responses. J Virol (2016) 90(5):2208-20. doi:10.1128/JVI.02278-15
11. Soghoian DZ, Jessen H, Flanders M, Sierra-Davidson K, Cutler S, Pertel T, et al. HIV-specific cytolytic CD4 T cell responses during acute HIV infection predict disease outcome. Sci Transl Med (2012) 4(123):123ra25. doi:10.1126/scitranslmed.3003165
12. Lusso P. HIV and the chemokine system: 10 years later. EMBO J (2006) 25(3):447-56. doi:10.1038/sj.emboj.7600947
13. Boaz MJ, Waters A, Murad S, Easterbrook PJ, Vyakarnam A. Presence of HIV-1 Gag-specific IFN-gamma+IL-2+ and CD28+IL-2+ CD4 T cell responses is associated with nonprogression in HIV-1 infection. J Immunol (2002) 169(11):6376-85. doi:10.4049/jimmunol.169.11.6376
14. Ranasinghe S, Cutler S, Davis I, Lu R, Soghoian DZ, Qi Y, et al. Association of HLA-DRB1-restricted CD4(+) T cell responses with HIV immune control. Nat Med (2013) 19(7):930-3. doi:10.1038/nm.3229
15. Virgin HW, Walker BD. Immunology and the elusive AIDS vaccine. Nature (2010) 464(7286):224-31. doi:10.1038/nature08898
16. Fonseca SG, Coutinho-Silva A, Fonseca LA, Segurado AC, Moraes SL, Rodrigues H, et al. Identification of novel consensus CD4 T-cell epitopes from clade B HIV-1 whole genome that are frequently recognized by HIV-1 infected patients. AIDS (2006) 20(18):2263-73. doi:10.1097/01.aids.0000253353.48331.5f
17. Rosa DS, Ribeiro SP, Fonseca SG, Almeida RR, Santana VC, Apostolico JdeS, et al. Multiple approaches for increasing the immunogenicity of an epitope-based anti-HIV vaccine. AIDS Res Hum Retroviruses (2015) 31(11):1077-88. doi:10.1089/AID.2015.0101
18. Ribeiro SP, Rosa DS, Fonseca SG, Mairena EC, Postol E, Oliveira SC, et al. A vaccine encoding conserved promiscuous HIV CD4 epitopes induces broad T cell responses in mice transgenic to multiple common HLA class II molecules. PLoS One (2010) 5(6):e11072. doi:10.1371/journal.pone.0011072
19. Rosa DS, Ribeiro SP, Almeida RR, Mairena EC, Postol E, Kalil J, et al. A DNA vaccine encoding multiple HIV CD4 epitopes elicits vigorous polyfunctional, long-lived CD4+ and CD8+ T cell responses. PLoS One (2011) 6(2):e16921. doi:10.1371/journal.pone.0016921
20. Wedrychowicz H. Antiparasitic DNA vaccines in 21st century. Acta Parasitol (2015) 60(2):179-89. doi:10.1515/ap-2015-0026
21. Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat Rev Genet (2008) 9(10):776-88. doi:10.1038/nrg2432
22. Rosa DS, Apostolico JdeS, Boscardin SB. DNA vaccines: how much have we accomplished in the last 25 years? J Vaccines Vaccin (2015) 6:283. doi:10.4172/2157-7560.1000283
23. Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol (2013) 31:563-604. doi:10.1146/annurev-immunol-020711-074950
24. Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nat Rev Immunol (2002) 2(3):151-61. doi:10.1038/nri746
25. Dudziak D, Kamphorst AO, Heidkamp GF, Buchholz VR, Trumpfheller C, Yamazaki S, et al. Differential antigen processing by dendritic cell subsets in vivo. Science (2007) 315(5808):107-11. doi:10.1126/science.1136080
26. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med (2001) 194(6):769-79. doi:10.1084/jem.194.6.769
27. Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S, Soares H, et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med (2004) 199(6):815-24. doi:10.1084/jem.20032220
28. Boscardin SB, Hafalla JC, Masilamani RF, Kamphorst AO, Zebroski HA, Rai U, et al. Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses. J Exp Med (2006) 203(3):599-606. doi:10.1084/jem.20051639
29. Tewari K, Flynn BJ, Boscardin SB, Kastenmueller K, Salazar AM, Anderson CA, et al. Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and alphaDEC-CSP in non human primates. Vaccine (2010) 28(45):7256-66. doi:10.1016/j.vaccine.2010.08.098
30. Rampazo EV, Amorim KN, Yamamoto MM, Panatieri RH, Rodrigues MM, Boscardin SB. Antigen targeting to dendritic cells allows the identification of a CD4 T-cell epitope within an immunodominant Trypanosoma cruzi antigen. PLoS One (2015) 10(2):e0117778. doi:10.1371/journal.pone.0117778
31. Silva-Sanchez A, Meza-Perez S, Flores-Langarica A, Donis-Maturano L, Estrada-Garcia I, Calderon-Amador J, et al. ESAT-6 targeting to DEC205+ antigen presenting cells induces specific-T cell responses against ESAT-6 and reduces pulmonary infection with virulent Mycobacterium tuberculosis. PLoS One (2015) 10(4):e0124828. doi:10.1371/journal.pone.0124828
32. Trumpfheller C, Caskey M, Nchinda G, Longhi MP, Mizenina O, Huang Y, et al. The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. Proc Natl Acad Sci U S A (2008) 105(7):2574-9. doi:10.1073/pnas.0711976105
33. Trumpfheller C, Finke JS, Lopez CB, Moran TM, Moltedo B, Soares H, et al. Intensified and protective CD4+ T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine. J Exp Med (2006) 203(3):607-17. doi:10.1084/jem.20052005
34. Ruane D, Do Y, Brane L, Garg A, Bozzacco L, Kraus T, et al. A dendritic cell targeted vaccine induces long-term HIV-specific immunity within the gastrointestinal tract. Mucosal Immunol (2016) 9(5):1340-52. doi:10.1038/mi.2015.133
35. Henriques HR, Rampazo EV, Goncalves AJ, Vicentin EC, Amorim JH, Panatieri RH, et al. Targeting the non-structural protein 1 from dengue virus to a dendritic cell population confers protective immunity to lethal virus challenge. PLoS Negl Trop Dis (2013) 7(7):e2330. doi:10.1371/journal.pntd.0002330
36. Idoyaga J, Lubkin A, Fiorese C, Lahoud MH, Caminschi I, Huang Y, et al. Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A. Proc Natl Acad Sci U S A (2011) 108(6):2384-9. doi:10.1073/pnas.1019547108
37. Cheong C, Choi JH, Vitale L, He LZ, Trumpfheller C, Bozzacco L, et al. Improved cellular and humoral immune responses in vivo following targeting of HIV Gag to dendritic cells within human anti-human DEC205 monoclonal antibody. Blood (2010) 116(19):3828-38. doi:10.1182/blood-2010-06-288068
38. Nchinda G, Amadu D, Trumpfheller C, Mizenina O, Uberla K, Steinman RM. Dendritic cell targeted HIV gag protein vaccine provides help to a DNA vaccine including mobilization of protective CD8+ T cells. Proc Natl Acad Sci U S A (2010) 107(9):4281-6. doi:10.1073/pnas.1000621107
39. Ratto-Kim SCJ, Cox JH, Excler JL, Valencia-Micolta A, Thelian D, Lo V, et al. Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens. PLoS One (2012) 7(9):e45840. doi:10.1371/journal.pone.0045840
40. Iyer SS, Gangadhara S, Victor B, Shen X, Chen X, Nabi R, et al. Virus-like particles displaying trimeric simian immunodeficiency virus (SIV) envelope gp160 enhance the breadth of DNA/modified vaccinia virus ankara SIV vaccine-induced antibody responses in rhesus macaques. J Virol (2016) 90(19):8842-54. doi:10.1128/JVI.01163-16
41. Wille-Reece U, Flynn BJ, Lore K, Koup RA, Miles AP, Saul A, et al. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J Exp Med (2006) 203(5):1249-58. doi:10.1084/jem.20052433
42. Cabrera-Mora M, Fonseca JA, Singh B, Zhao C, Makarova N, Dmitriev I, et al. A recombinant chimeric Ad5/3 vector expressing a multistage plasmodium antigen induces protective immunity in mice using heterologous prime-boost immunization regimens. J Immunol (2016) 197(7):2748-61. doi:10.4049/jimmunol.1501926
43. Livingston B, Crimi C, Newman M, Higashimoto Y, Appella E, Sidney J, et al. A rational strategy to design multiepitope immunogens based on multiple Th lymphocyte epitopes. J Immunol (2002) 168(11):5499-506. doi:10.4049/jimmunol.168.11.5499
44. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF, et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis (2005) 191(5):654-65. doi:10.1086/428404
45. Watkins DI. The hope for an HIV vaccine based on induction of CD8+ T lymphocytes-a review. Mem Inst Oswaldo Cruz (2008) 103(2):119-29. doi:10.1590/S0074-02762008000200001
46. Watkins DI, Burton DR, Kallas EG, Moore JP, KoffWC. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med (2008) 14(6):617-21. doi:10.1038/nm.f.1759
47. Vaccari M, Boasso A, Ma ZM, Cecchinato V, Venzon D, Doster MN, et al. CD4+ T-cell loss and delayed expression of modulators of immune responses at mucosal sites of vaccinated macaques following SIV(mac251) infection. Mucosal Immunol (2008) 1(6):497-507. doi:10.1038/mi.2008.60
48. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med (2002) 196(12):1627-38. doi:10.1084/jem.20021598
49. Do Y, Koh H, Park CG, Dudziak D, Seo P, Mehandru S, et al. Targeting of LcrV virulence protein from Yersinia pestis to dendritic cells protects mice against pneumonic plague. Eur J Immunol (2010) 40(10):2791-6. doi:10.1002/eji.201040511
50. Stahl-Hennig C, Eisenblatter M, Jasny E, Rzehak T, Tenner-Racz K, Trumpfheller C, et al. Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS Pathog (2009) 5(4):e1000373. doi:10.1371/journal.ppat.1000373
51. Soares H, Waechter H, Glaichenhaus N, Mougneau E, Yagita H, Mizenina O, et al. A subset of dendritic cells induces CD4+ T cells to produce IFN-gamma by an IL-12-independent but CD70-dependent mechanism in vivo. J Exp Med (2007) 204(5):1095-106. doi:10.1084/jem.20070176
52. Gurer C, Strowig T, Brilot F, Pack M, Trumpfheller C, Arrey F, et al. Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses. Blood (2008) 112(4):1231-9. doi:10.1182/blood-2008-03-148072
53. Owen RE, Heitman JW, Hirschkorn DF, Lanteri MC, Biswas HH, Martin JN, et al. HIV+ elite controllers have low HIV-specific T-cell activation yet maintain strong, polyfunctional T-cell responses. AIDS (2010) 24(8):1095-105. doi:10.1097/QAD.0b013e3283377a1e
54. Emu B, Sinclair E, Favre D, Moretto WJ, Hsue P, Hoh R, et al. Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment. J Virol (2005) 79(22):14169-78. doi:10.1128/JVI.79.22.14169-14178.2005
55. Potter SJ, Lacabaratz C, Lambotte O, Perez-Patrigeon S, Vingert B, Sinet M, et al. Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study. J Virol (2007) 81(24):13904-15. doi:10.1128/JVI.01401-07
56. Ferre AL, Hunt PW, Critchfield JW, Young DH, Morris MM, Garcia JC, et al. Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. Blood (2009) 113(17):3978-89. doi:10.1182/blood-2008-10-182709
57. Corey L, Gilbert PB, Tomaras GD, Haynes BF, Pantaleo G, Fauci AS. Immune correlates of vaccine protection against HIV-1 acquisition. Sci Transl Med (2015) 7(310):310rv7. doi:10.1126/scitranslmed.aac7732
58. Jiang W, Swiggard WJ, Heufler C, Peng M, Mirza A, Steinman RM, et al. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature (1995) 375(6527):151-5. doi:10.1038/375151a0
59. Saluja SS, Hanlon DJ, Sharp FA, Hong E, Khalil D, Robinson E, et al. Targeting human dendritic cells via DEC-205 using PLGA nanoparticles leads to enhanced cross-presentation of a melanoma-associated antigen. Int J Nanomedicine (2014) 9:5231-46. doi:10.2147/IJN.S66639
60. Cruz LJ, Rosalia RA, Kleinovink JW, Rueda F, Lowik CW, Ossendorp F. Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8(+) T cell response: a comparative study. J Control Release (2014) 192:209-18. doi:10.1016/j.jconrel.2014.07.040
61. Kastenmuller W, Kastenmuller K, Kurts C, Seder RA. Dendritic cell-targeted vaccines-hope or hype? Nat Rev Immunol (2014) 14(10):705-11. doi:10.1038/nri3727
62. Costa M, Pollara J, Edwards RW, Seaman M, Gorny MK, Montefiori D, et al. Fc receptor mediated activities by Env-specific human mAbs generated from volunteers receiving the DNA prime-protein boost HIV vaccine DP6-001. J Virol (2016) 90(22):10362-78. doi:10.1128/JVI.01458-16
63. Woodland DL. Jump-starting the immune system: prime-boosting comes of age. Trends Immunol (2004) 25(2):98-104. doi:10.1016/j.it.2003.11.009
64. Lu S. Combination DNA plus protein HIV vaccines. Springer Semin Immunopathol (2006) 28(3):255-65. doi:10.1007/s00281-006-0028-1
65. Flynn BJ, Kastenmuller K, Wille-Reece U, Tomaras GD, Alam M, Lindsay RW, et al. Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. Proc Natl Acad Sci U S A (2011) 108(17):7131-6. doi:10.1073/pnas.1103869108
66. Sekaly RP. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med (2008) 205(1):7-12. doi:10.1084/jem.20072681
67. Wilson NA, Keele BF, Reed JS, Piaskowski SM, MacNair CE, Bett AJ, et al. Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge. J Virol (2009) 83(13):6508-21. doi:10.1128/JVI.00272-09
68. Martins MA, Wilson NA, Reed JS, Ahn CD, Klimentidis YC, Allison DB, et al. T-cell correlates of vaccine efficacy after a heterologous simian immunodeficiency virus challenge. J Virol (2010) 84(9):4352-65. doi:10.1128/JVI.02365-09
69. Corey L, McElrath MJ, Kublin JG. Post-step modifications for research on HIV vaccines. AIDS (2009) 23(1):3-8. doi:10.1097/QAD.0b013e32830e6d6d